国际肿瘤学杂志

国际肿瘤学杂志 ›› 2019, Vol. 46 ›› Issue (2): 98-101.doi: 10.3760/cma.j.issn.1673-422X.2019.02.008

• 综述 • 上一篇    下一篇

甲状腺未分化癌的靶向药物治疗进展

 武元元, 王军   

  1. 甘肃省肿瘤医院头颈外科，兰州730050
  • 出版日期:2019-02-08 发布日期:2019-04-03
  • 通讯作者: 王军，Email: jack3376@live.cn E-mail:jack3376@live.cn

Advancement of targeted agents in the treatment of anaplastic thyroid carcinoma

Wu Yuanyuan, Wang Jun   

  1. Department of Head and Neck Surgery, Gansu Provincial Cancer Hospital, Lanzhou 730050, China
  • Online:2019-02-08 Published:2019-04-03
  • Contact: Wang Jun, Email: jack3376@live.cn E-mail:jack3376@live.cn

PDF

846

摘要： 甲状腺未分化癌发病率低，恶性程度高，生存期仅为数周或数月。尽管多学科综合治疗可延长部分患者的生存时间，但目前仍无有效提高生存率的标准治疗方法。肿瘤分子生物学的发展促使人们从基因水平上认识甲状腺未分化癌的发生、发展机制，从而为靶向治疗提供了理论依据。一些靶向药物已被批准用于治疗难治性晚期分化型甲状腺癌，同时靶向药物治疗甲状腺未分化癌的临床试验也为患者带来了新的希望。

关键词: 甲状腺肿瘤, 基因, 突变, 药物疗法, 联合

Abstract: Anaplastic thyroid carcinoma (ATC) is very rare and aggressive in humans, and its survival time is most often expressed in weeks or months. For now, there is no standard treatment for longterm survival, even if the multidisciplinary approach could prolong survival in some patients. The development of oncomolecular biology promotes the understanding about the pathogenesis of ATC from genetic level, and then providing a theoretical basis for targeted therapy. Some targeted drugs have been approved for the treatment of refractory advanced differentiated thyroid cancer, in the meantime, the clinical trials of targeted therapy bring new hope for ATC patients.

Key words: Thyroid neoplasms, Genes, Mutation, Drug therapy, combination